Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory R Pond

Showing results (1-10 of 255) with videos related to

Pageof 26
Sort By:
Clinical Trials (London, England)|April 23, 2011
Quantitative evaluation of single-arm versus randomized phase II cancer clinical trialsGregory R Pond, Saqib Abbasi
World Journal of Urology|April 15, 2018
Early tumor shrinkage is independently associated with improved overall survival among patients with metastatic renal cell carcinoma: a validation study using the COMPARZ cohortViktor Grünwald, Marion Dietrich, Gregory R Pond
European Urology|September 30, 2015
Reply from Authors re: Tracy L. Rose, Matthew I. Milowsky. A Small Step Toward Improving Salvage Treatment for Metastatic Bladder Cancer--At What Cost? Eur Urol 2016;69:642-44: Combination Chemotherapy as a Viable Salvage Therapy Strategy for Advanced Urothelial CarcinomaGuru Sonpavde, Gregory R Pond, Joaquim Bellmunt
JAMA Oncology|December 23, 2021
Metformin-A Thought-provoking Addition to Anticancer Therapies-ReplyTheodoros Tsakiridis, Gregory R Pond, James Wright
Current Oncology (Toronto, Ont.)|July 21, 2021
Patterns of Relapse in Small Cell Lung Cancer: Competing Risks of Thoracic versus CNS RelapsePeter M Ellis, Anand Swaminath, Gregory R Pond
European Journal of Cancer (Oxford, England : 1990)|June 29, 2010
The unclear zone in phase II clinical trialsSabrina Allegro, Gregory R Pond, Sébastien J Hotte
Journal of the National Cancer Institute|September 8, 2025
Success in oncology phase 3 trials: a small P value or patient valueLaure-Anne Teuwen, Gregory R Pond, Bishal Gyawali
Current Oncology (Toronto, Ont.)|August 27, 2025
CAPOX vs. FOLFOX for Colorectal Cancer-Real World Outcomes in Ontario, CanadaDeepro Chowdhury, Gregory R Pond, John R Goffin
Clinical Lung Cancer|July 5, 2016
Assessment of Referral and Chemotherapy Treatment Patterns for Elderly Patients With Non-small-Cell Lung CancerDavid E Dawe, Gregory R Pond, Peter M Ellis
JAMA Oncology|March 10, 2022
Biased Evaluation in Cancer Drug Trials-How Use of Progression-Free Survival as the Primary End Point Can MisleadIan F Tannock, Gregory R Pond, Christopher M Booth
Pageof 26

Showing results (1-10 of 255) with videos related to

Sort By:
Pageof 26
Clinical Trials (London, England)|April 23, 2011
Quantitative evaluation of single-arm versus randomized phase II cancer clinical trialsGregory R Pond, Saqib Abbasi
World Journal of Urology|April 15, 2018
Early tumor shrinkage is independently associated with improved overall survival among patients with metastatic renal cell carcinoma: a validation study using the COMPARZ cohortViktor Grünwald, Marion Dietrich, Gregory R Pond
European Urology|September 30, 2015
Reply from Authors re: Tracy L. Rose, Matthew I. Milowsky. A Small Step Toward Improving Salvage Treatment for Metastatic Bladder Cancer--At What Cost? Eur Urol 2016;69:642-44: Combination Chemotherapy as a Viable Salvage Therapy Strategy for Advanced Urothelial CarcinomaGuru Sonpavde, Gregory R Pond, Joaquim Bellmunt
JAMA Oncology|December 23, 2021
Metformin-A Thought-provoking Addition to Anticancer Therapies-ReplyTheodoros Tsakiridis, Gregory R Pond, James Wright
Current Oncology (Toronto, Ont.)|July 21, 2021
Patterns of Relapse in Small Cell Lung Cancer: Competing Risks of Thoracic versus CNS RelapsePeter M Ellis, Anand Swaminath, Gregory R Pond
European Journal of Cancer (Oxford, England : 1990)|June 29, 2010
The unclear zone in phase II clinical trialsSabrina Allegro, Gregory R Pond, Sébastien J Hotte
Journal of the National Cancer Institute|September 8, 2025
Success in oncology phase 3 trials: a small P value or patient valueLaure-Anne Teuwen, Gregory R Pond, Bishal Gyawali
Current Oncology (Toronto, Ont.)|August 27, 2025
CAPOX vs. FOLFOX for Colorectal Cancer-Real World Outcomes in Ontario, CanadaDeepro Chowdhury, Gregory R Pond, John R Goffin
Clinical Lung Cancer|July 5, 2016
Assessment of Referral and Chemotherapy Treatment Patterns for Elderly Patients With Non-small-Cell Lung CancerDavid E Dawe, Gregory R Pond, Peter M Ellis
JAMA Oncology|March 10, 2022
Biased Evaluation in Cancer Drug Trials-How Use of Progression-Free Survival as the Primary End Point Can MisleadIan F Tannock, Gregory R Pond, Christopher M Booth
Pageof 26